Milk thistle & HIV
This article was originally published in The Tan Sheet
Executive Summary
"Milk thistle in commonly administered dosages should not interfere with indinavir therapy in patients infected with" HIV, researchers report in May Pharmacotherapy. Stephen Piscitelli, et al., National Institutes of Health, conducted prospective open-label study of 10 healthy volunteers and found an insignificant 9% reduction in presence of HIV drug indinavir after three weeks of dosing with milk thistle. Participants received four doses of indinavir 800 mg at baseline, then took 175 mg milk thistle (containing 153 mg silymarin) three times/day for three weeks. In similar research, Piscitelli et al. had shown HIV drug interactions with garlic, St. John's wort (1"The Tan Sheet" Dec. 10, 2001, p. 11)...
You may also be interested in...
Garlic Supplements, Protease Inhibitor Interactions Troublesome – NIH Study
A National Institutes of Health study finding garlic supplements reduce plasma concentration levels of an HIV protease inhibitor by approximately 50% could spur drug interaction warnings on such supplements
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.